Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001
   Google Scholar   
Citation:
ASCO Annual Meeting Oral abstract
Meeting Instance:
ASCO 2007
Year:
2007
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Parents:
None
Children:
268  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Networks:
 
Study
ACOSOG-Z9001
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: